• GMP Certified Amlodipine Besylate Tablet 5mg Shinepharm
  • GMP Certified Amlodipine Besylate Tablet 5mg Shinepharm
  • GMP Certified Amlodipine Besylate Tablet 5mg Shinepharm
  • GMP Certified Amlodipine Besylate Tablet 5mg Shinepharm
  • GMP Certified Amlodipine Besylate Tablet 5mg Shinepharm
  • GMP Certified Amlodipine Besylate Tablet 5mg Shinepharm

GMP Certified Amlodipine Besylate Tablet 5mg Shinepharm

Application: Internal Medicine
Usage Mode: For oral administration
Suitable for: Elderly, Children, Adult
State: Solid
Shape: Tablet
Type: Organic Chemicals
Samples:
US$ 0/Box 1 Box(Min.Order)
| Request Sample
Customization:

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Manufacturer/Factory, Trading Company

Basic Info.

Model NO.
AMC12097-01
Pharmaceutical Technology
Chemical Synthesis
Delivery Time
30~60 Days
OEM/ODM
Support
Standard Available
Cp, Bp
Transport Package
Carton
Specification
5mg, 10x10tables
Trademark
Shinepharm
Origin
China
HS Code
3004909099
Production Capacity
1000000 Boxes/Month

Product Description

 

GMP Certified Amlodipine Besylate Tablet 5mg Shinepharm

Amlodipine Besylate Tablet

Indications:
Hypertension;Chronic stable angina pectoris;Vasospastic (Prinzmetal's) angina

Dosage and Administration
Usage: Tablet for oral administration.

Dosage:
1.Adults 
For both hypertension and angina the usual initial dose is 5 mg Istin once daily which may be increased to a maximum dose of 10 mg depending on the individual patient's response.

2.Elderly patients:Normal dosage regimens are recommended in the elderly
Patients with hepatic impairment
Amlodipine should be initiated at the lowest dose and titrated slowly in patients with severe hepatic impairment.

3.Paediatric population:The recommended antihypertensive oral dose in paediatric patients ages 6-17 years is 2.5 mg once daily as a starting dose, up-titrated to 5 mg once daily if blood pressure goal is not achieved after 4 weeks.

Precautions & Warning:
Patients with cardiac failure: should be treated with caution.

Patients with hepatic impairment:Slow dose titration and careful monitoring may be required in patients with severe hepatic impairment.

Elderly patients:In the elderly increase of the dosage should take place with care

Patients with renal impairment: Amlodipine is not dialysable.

Contraindications
1. hypersensitivity to dihydropyridine derivatives, amlodipine or to any of the excipients

2. severe hypotension.

3.shock (including cardiogenic shock).

4. obstruction of the outflow tract of the left ventricle (e.g., high grade aortic stenosis).

5. haemodynamically unstable heart failure after acute myocardial infarction.

Adverse Reactions
Summary of the safety profile

The most commonly reported adverse reactions during treatment are somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, oedema and fatigue.

Storage instructions:
Do not store above 25°C

 

GMP Certified Amlodipine Besylate Tablet 5mg ShinepharmGMP Certified Amlodipine Besylate Tablet 5mg Shinepharm
GMP Certified Amlodipine Besylate Tablet 5mg ShinepharmGMP Certified Amlodipine Besylate Tablet 5mg ShinepharmGMP Certified Amlodipine Besylate Tablet 5mg ShinepharmGMP Certified Amlodipine Besylate Tablet 5mg Shinepharm

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now